The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601)
Abstract
Targeted therapies for cancer is a rapidly advancing field, but the identification of tumor-specific ligands has proven difficult. Chlorotoxin (CTX) is a small, 36 amino acid neurotoxin isolated from the venom of the Giant Yellow Israeli scorpion Leiurus Quinquestriatus. Interestingly, the peptide has been found to preferentially bind to a variety of human malignancies, but shows little or no binding to normal human tissues. A synthetic version of this peptide (TM-601) has been manufactured and covalently linked to iodine 131 (131I-TM-601) as a means of targeting radiation to tumor cells. Preclinical studies and Phase I clinical trials have been completed in patients with recurrent glioma, a type of malignant brain tumor. These studies demonstrated that intracavitary dosing of 131I-TM-601 appears safe, minimally toxic, and binds malignant glioma with high affinity and for long durations. A Phase II trial of this agent using higher doses of radioactivity and repeated local administrations is underway. In addition, enrolment has begun in a Phase I trial evaluating whether systemically delivered 131I-TM-601 can be used to image metastatic solid tumors and primary gliomas. Due to its small size, selective tumor binding properties, minimal toxicity and relative ease of manipulation, CTX represents a potentially important targeting agent for many cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Epidemiology and etiology of gliomas
Ohgaki, H., & Kleihues, P. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-0991-y · Cited by 1,252
Stummer, W., Novotny, A., Stepp, H., Goetz, C., Bise, K., & Reulen, H. J. (2000) · Journal of Neurosurgery · doi:10.3171/jns.2000.93.6.1003 · Cited by 881
Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms
Kelly, P. J., Daumas-Duport, C., Kispert, D. B., Kall, B. A., Scheithauer, B. W., & Illig, J. J. (1987) · Journal of Neurosurgery · doi:10.3171/jns.1987.66.6.0865 · Cited by 798
Rainov, N. G. (2000) · Human Gene Therapy · doi:10.1089/104303400750038499 · Cited by 698
Laws, E. R., Parney, I. F., Huang, W., Anderson, F., Morris, A. M., Asher, A., Lillehei, K. O., Bernstein, M., Brem, H., Sloan, A., et al. (2003) · Journal of Neurosurgery · doi:10.3171/jns.2003.99.3.0467 · Cited by 670
Factors influencing survival in high-grade gliomas
Buckner, J. C. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.11.031 · Cited by 443
Diffusion-tensor imaging of white matter tracts in patients with cerebral neoplasm
Witwer, B. P., Moftakhar, R., Hasan, K. M., Deshmukh, P., Haughton, V., Field, A., Arfanakis, K., Noyes, J., Moritz, C. H., Meyerand, M. E., et al. (2002) · Journal of Neurosurgery · doi:10.3171/jns.2002.97.3.0568 · Cited by 431
Chlorotoxin Inhibits Glioma Cell Invasion via Matrix Metalloproteinase-2
Deshane, J., Garner, C. C., & Sontheimer, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m205662200 · Cited by 415
Cited by
Venoms as a platform for human drugs: translating toxins into therapeutics
King, G. F. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.621940 · Cited by 516
Role of Ion Channels and Transporters in Cell Migration
Schwab, A., Fabian, A., Hanley, P. J., & Stock, C. (2012) · Physiological Reviews · doi:10.1152/physrev.00018.2011 · Cited by 420
Niosomes: A review on niosomal research in the last decade
Bhardwaj, P., Tripathi, P., Gupta, R., & Pandey, S. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101581 · Cited by 366
Scorpion venom components as potential candidates for drug development
Ortiz, E., Gurrola, G. B., Schwartz, E. F., & Possani, L. D. (2015) · Toxicon · doi:10.1016/j.toxicon.2014.11.233 · Cited by 335
In Vivo MRI Detection of Gliomas by Chlorotoxin‐Conjugated Superparamagnetic Nanoprobes
Sun, C., Veiseh, O., Gunn, J., Fang, C., Hansen, S., Lee, D., Sze, R., Ellenbogen, R. G., Olson, J., & Zhang, M. (2008) · Small · doi:10.1002/smll.200700784 · Cited by 329
Metadata
- Authors
- Mamelak, A. N., & Jacoby, D. B.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa Healthcare
- Published
- 2007-03
- Volume
- 4
- Issue
- 2
- Pages
- 175-186
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2140222552
- Cited by
- 273
- References
- 43
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). https://app.cochat.ai/papers/10.1517/17425247.4.2.175
- The paper
- Mamelak, A. N., & Jacoby, D. B. (2007). Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opinion on Drug Delivery. https://doi.org/10.1517/17425247.4.2.175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.